Basking Biosciences, Inc. — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
BB-031The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset. Participants will be randomized to receive one dose of either the investigational drug or placebo and will be followed for 90 days. A total of 228 patients are planned in this study.	Accident vasculaire cérébral	Phase 2	À vérifier	United States, Australia, Canada	À vérifier
BB-031The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset. Participants will be randomized to receive one dose of either the investigational drug or placebo and will be followed for 90 days. A total of 228 patients are planned in this study.	Accident vasculaire cérébral	Phase 2	À vérifier	United States, Australia, Canada	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
BB-031	Accident vasculaire cérébral	Phase 2	NCT06226805	Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.